Immunovant, Inc. (IMVT)

NASDAQ: IMVT · IEX Real-Time Price · USD
32.31
-0.21 (-0.65%)
Mar 28, 2024, 4:00 PM EDT - Market closed

Total Valuation

Immunovant has a market cap or net worth of $4.65 billion. The enterprise value is $3.96 billion.

Market Cap 4.65B
Enterprise Value 3.96B

Important Dates

The next estimated earnings date is Monday, May 20, 2024, before market open.

Earnings Date May 20, 2024
Ex-Dividend Date n/a

Share Statistics

Immunovant has 145.29 million shares outstanding. The number of shares has increased by 12.40% in one year.

Shares Outstanding 145.29M
Shares Change (YoY) +12.40%
Shares Change (QoQ) +10.19%
Owned by Insiders (%) 55.50%
Owned by Institutions (%) 47.64%
Float 64.47M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio n/a
Forward PS n/a
PB Ratio 6.84
P/FCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 22.14, with a Debt / Equity ratio of 0.00.

Current Ratio 22.14
Quick Ratio 21.56
Debt / Equity 0.00
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage n/a

Financial Efficiency

Return on equity (ROE) is -61.10% and return on invested capital (ROIC) is -39.15%.

Return on Equity (ROE) -61.10%
Return on Assets (ROA) -55.30%
Return on Capital (ROIC) -39.15%
Revenue Per Employee n/a
Profits Per Employee -$1.48M
Employee Count 164
Asset Turnover n/a
Inventory Turnover n/a

Taxes

Income Tax -656,000
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +107.80% in the last 52 weeks. The beta is 0.72, so Immunovant's price volatility has been lower than the market average.

Beta (1Y) 0.72
52-Week Price Change +107.80%
50-Day Moving Average 35.47
200-Day Moving Average 31.08
Relative Strength Index (RSI) 45.94
Average Volume (30 Days) 1,268,445

Short Selling Information

The latest short interest is 9.35 million, so 6.44% of the outstanding shares have been sold short.

Short Interest 9.35M
Short Previous Month 8.68M
Short % of Shares Out 6.44%
Short % of Float 14.51%
Short Ratio (days to cover) 7.93

Income Statement

Revenue n/a
Gross Profit n/a
Operating Income -266.09M
Pretax Income -244.11M
Net Income -243.45M
EBITDA -242.72M
EBIT -244.11M
Earnings Per Share (EPS) -$1.83
Full Income Statement

Balance Sheet

The company has $690.94 million in cash and $306,000 in debt, giving a net cash position of $690.63 million or $4.75 per share.

Cash & Cash Equivalents 690.94M
Total Debt 306,000
Net Cash 690.63M
Net Cash Per Share $4.75
Equity / Book Value 679.34M
Book Value Per Share 4.68
Working Capital 678.67M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$210.32 million and capital expenditures -$236,000, giving a free cash flow of -$210.56 million.

Operating Cash Flow -210.32M
Capital Expenditures -236,000
Free Cash Flow -210.56M
FCF Per Share -$1.46
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

Immunovant does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -12.40%
Shareholder Yield -12.40%
Earnings Yield -5.24%
FCF Yield -4.53%
Dividend Details

Analyst Forecast

The average price target for Immunovant is $44.67, which is 38.25% higher than the current price. The consensus rating is "Strong Buy".

Price Target $44.67
Price Target Difference 38.25%
Analyst Consensus Strong Buy
Analyst Count 18
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Altman Z-Score n/a
Piotroski F-Score 2